144-55-8Relevant articles and documents
Anion inhibition profiles of the γ-carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei responsible of melioidosis and highly drug resistant to common antibiotics
Del Prete, Sonia,Vullo, Daniela,Di Fonzo, Pietro,Osman, Sameh M.,AlOthman, Zeid,Supuran, Claudiu T.,Capasso, Clemente
, p. 575 - 580 (2017)
Burkholderia pseudomallei is a Gram-negative saprophytic bacterium responsible of melioidosis, an endemic disease of tropical and sub-tropical regions of the world. A recombinant γ-CA (BpsγCA) identified in the genome of this bacterium was cloned and puri
Belton, P. S.,Clarke, T. A.,Meyrick, D.
, p. 614 - 615 (1981)
CO2 capture and release of Na0.7MnO2.05 under water vapor at 25–150?°C
Yanase, Ikuo,Takano, Takuya
, p. 212 - 218 (2019)
Sodium manganates with a layered structure, Na0.7MnO2.05, have been applied to a novel material for CCUS (CO2 capture, utilization, and storage), capable of capturing CO2 at 25 °C in the presence of water vapor and releasing CO2 at 150 °C. The temperatures of capturing and releasing CO2 of Na0.7MnO2.05 were remarkably lower than those of other traditional metal oxides. The CO2 absorption and desorption properties of Na0.7MnO2.05 were investigated by various methods, such as thermogravimetry, Fourier transform infrared spectroscopy, X-ray diffractometry, and gas chromatography. These investigations confirmed that Na0.7MnO2.05 absorbed CO2 at 25 °C in the presence of water vapor to produce NaHCO3 and a birnessite and the CO2 absorption was promoted by increasing relative humidity and CO2 concentration. The CO2 absorption at 25 °C of Na0.7MnO2.05 was promoted by the formation of a strong basic solution on Na0.7MnO2.05, caused by the elution of Na ions from the interlayer of Na0.7MnO2.05 into water, adsorbed on the Na0.7MnO2.05 surface. Furthermore, Na0.7MnO2.05 was regenerated by heating the CO2-absorbed Na0.7MnO2.05 at temperatures as low as 150 °C. The low-temperature regeneration indicates that Na0.7MnO2.05 can be a low-energy consumption material for capturing and releasing CO2 at low temperatures.
Bamberger, C. E.,Robinson, Paul R.
, p. 133 - 138 (1980)
Investigation of the Formation of Wegscheiderite, Na2CO3*3NaHCO3
Ball, Matthew C.,Clarke, Rosemary A.,Strachan, Alec N.
, p. 3683 - 3686 (1991)
The reaction of sodium carbonate with water vapour and carbon dioxide has been studied in the temperature range 343-368 K in pure carbon dioxide, and at pressures of water vapour between 1 * 104 and 5 * 104 N m-2.The produ
Carbon dioxide conversion into the reaction intermediate sodium formate for the synthesis of formic acid
Masood, Muhammad Hanan,Haleem, Noor,Shakeel, Iqra,Jamal, Yousuf
, p. 5165 - 5180 (2020/09/03)
Increased carbon dioxide (CO2) emissions from anthropogenic activities are a contributing factor to the growing global warming worldwide. The economical method to recover and effectively reuse CO2 is through adsorption and absorption. In this study, CO2 is absorbed into the solution of sodium hydroxide having various concentrations (0.01, 0.1, 0.5, 1.0, 3.0 and 5.0?N), and the impact of the solution pH on the various product formation was observed. The resultant products formed at different pH of the absorbing solution are sodium carbonate at pH 10, Trona at pH 9, and sodium hydrogen carbonate at pH 8. The products formed are confirmed through X-ray diffraction analysis. After pH optimization, the sodium hydrogen carbonate formed at pH 8 is converted into sodium formate through hydrogenation in the presence of nickel ferrite catalyst at 80 °C and atmospheric pressure. The sodium formate produced is then used as a precursor to synthesize formic acid upon simple reaction with sulfuric acid. A reaction % age yield of 79 ± 0.2% formic acid is noted. Condensed formic acid vapors are later analyzed, using a high performance?liquid chromatography for the qualitative analysis.
Macrocyclic MCL-1 inhibitors and methods of use
-
Paragraph 1023, (2019/02/28)
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
